Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) rose 3.8% during trading on Wednesday . The stock traded as high as $3.24 and last traded at $3.24, with a volume of 54,958 shares changing hands. The stock had previously closed at $3.12.

DRNA has been the topic of a number of analyst reports. Stifel Nicolaus decreased their target price on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, June 30th. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Sunday, June 26th. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Thursday, May 12th. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Jefferies Group restated a “buy” rating and set a $19.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $11.95.

The firm’s 50-day moving average price is $3.32 and its 200 day moving average price is $4.77. The company’s market cap is $68.60 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. Equities research analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.